A collaborative poster by APLUSA and Takeda, presented at the European Society for Medical Oncology (ESMO) 2025 Congress.
A joint effort recognized at ESMO 2025
We are proud to announce that a poster co-authored by APLUSA and Takeda was presented at ESMO 2025. Entitled “Understanding ALK+ NSCLC caregivers’ psychosociological burden: Findings from the study Living with ALK+ cancer in France”, the work explores the often-overlooked experiences of caregivers supporting patients with ALK-positive non-small cell lung cancer (NSCLC).
The study aimed to evaluate the indirect impact of ALK+ NSCLC on caregivers and to provide valuable insights into their unmet needs. Conducted in two phases, the Living with ALK+ cancer in France study combined qualitative exploration and quantitative data collected from 85 patients, 27 caregivers, and 50 oncologists between November 2024 and February 2025.
Key takeaways
The Living with ALK+ cancer in France study highlights the extensive challenges faced by caregivers of patients living with ALK+ NSCLC and emphasizes the need for comprehensive support systems addressing their daily-life difficulties and emotional strain.
- More caregivers than patients reported a major mental health impact of ALK+ NSCLC
- At least two-thirds experienced life-planning difficulties
- The most common challenges included fatigue, anxiety, sadness, and sleep problems
- Nearly three-quarters expressed a need for more information about ALK+ NSCLC and its progression
Understanding the psychosocial impact to improve care
This study reveals the considerable psychosocial burden faced by caregivers of patients with ALK+ NSCLC. It highlights the need for more comprehensive and structured support to help them manage the difficulties they encounter in their daily lives.
By shedding light on these realities, the Living with ALK+ cancer in France study presented at ESMO 2025 reinforces the importance of understanding and addressing the human side of cancer care, not only for patients but also for those who support them every day.
Explore more APLUSA scientific contributions
At APLUSA, we are committed to advancing understanding through evidence-based insights in oncology and beyond.
